Overview
CF PHARMTECH (2652)
CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs and other related medical products in China. It offers Shufeim...
- Open
- 4.840
- High
- 4.840
- Low
- 4.495
- Prev. Close
- 4.840
- Volume
- 1.11M
- Turnover
- 5.10M
- Avg Price
- 4.607
- Bid/Ask Ratio
- -80.00%
- Amplitude
- 7.13%
- 52wk High
- 39.500
- Volume Ratio
- 2.04
- Turnover Ratio
- 0.34%
- 52wk Low
- 4.495
- HK Mkt Cap
- 1.48B
- Market CapHKD
- 1.98B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.0181
- EPSDynamic
- -0.0561
- EPSStatic
- --
- BVPS
- 3.58
- P/B
- 1.28
- HK Shares
- 321.86M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 431.61M
- Min lot size
- 100
- Currency
- HKD
Daily Events
- Nov, 16
Changfeng Pharma opened at HK$4.84 and faded through the session, touching HK$4.50 at 14:44 BJ before closing at HK$4.65, down 3.93% on HK$5.01 million turnover, with the intraday low within 0.1% of the 52-week trough of HK$4.495 set a day earlier. The stock is down 86.31% year to date and 88.23% below its 25 February high of HK$39.50, still under both the MA20 of HK$5.331 and MA60 of HK$8.394. Results are mixed: Q2 2026 revenue of HK$121.4 million rose 58.37% yoy and the net loss narrowed 60.58% to HK$6.07 million, while Q1 revenue fell 18.02% and the loss widened 143.47%. First dosing of inhaled ILD candidate ICF004 in Phase I and a voluntary six-month lock-up extension by core management did not reverse the price weakness; PB is 1.30 and market value HK$2.01 billion. Though Q2 revenue rebounded and the loss narrowed yoy.
- Nov, 6
CF Pharmtech fell 5.75% to HK$5.160 in a spike-and-fade session: it opened at HK$5.470, probed HK$5.155 in the morning, rebounded to HK$5.465 at 13:28 before sliding to the day's low of HK$5.160 at the close on 1.0056 million shares worth HK$5.28 million. The move leaves it just 4.67% above the 52-week low of HK$4.93 set on 3 November, down 84.81% year-to-date and 86.94% below the 25 February peak of HK$39.50, with the price under both MA20 (HK$5.664) and MA60 (HK$9.564). Q2 revenue rose 58.37% year-on-year to HK$121.4 million and the net loss narrowed to HK$6.07 million with per-share loss of HK$0.0148, yet Q1 revenue fell 18.02% with a HK$5.97 million net loss, leaving the P/E negative and P/B at 1.44. Management voluntarily extended its lock-up by six months, the chairman added 19,300 shares near HK$6.92 and buybacks of about HK$499,600 continued, though turnover of only HK$5.28 million suggests thin support.
- Nov, 5
Opening at HK$5.320, which held as the session low, 2652.HK pushed to an 11:34 high of HK$5.505, eased to HK$5.340 in the afternoon and settled at HK$5.475, up 3.60%. The gain extends a roughly 11% rebound from the HK$4.93 record low set on 3 November, supported by core management's voluntary six-month lock-up extension, chairman Liang Wenqing's purchase of 19,300 shares at about HK$6.92, and buybacks of about HK$499,600 on each of 6-8 October. Fundamentals stay mixed: Q2 revenue rose 58.37% year on year to HK$121.4 million with the net loss narrowing to HK$6.07 million, while Q1 revenue fell 18.02% and its HK$5.97 million net loss widened 143.47%; the trailing PE is negative at -302.23 against PB of 1.53. The stock remains below its MA20 of HK$5.693 and MA60 of HK$9.747, down 83.88% year to date from HK$33.96 and 86.14% below the 25 February high of HK$39.50. Though profitability has yet to turn positive and the moving averages keep sloping down.
- Nov, 3
CF Pharmtech fell about 4.3% to HK$5.055 from the prior close of HK$5.285 after a spike-and-fade session: it opened at HK$5.08, touched HK$5.28 in the morning, then slid to HK$4.955 at 14:30 BJ, close to the 52-week low of HK$4.935 set the previous day. Support measures have not halted the slide: core management voluntarily extended its lock-up by six months, chairman Liang Wenqing bought 19,300 shares at about HK$6.92, and the company repurchased roughly 72,400 to 89,300 shares a day on October 6-8 for a combined HK$499,600. Fundamentals are mixed: Q2 2026 revenue rose 58.37% year on year to HK$121.4 million and the net loss narrowed to HK$6.07 million, while Q1 revenue fell 18.02%; PE is negative at -279.32 and PB 1.41 on a HK$2.18 billion market cap. The stock is down 85.1% year to date, 87.19% below its February 25 high of HK$39.5, and trades under its MA20 of HK$5.83. Though turnover was only HK$9.6 million at a 0.58% turnover rate, limiting the scale of selling.
- Oct, 22
Fading from the open, CF PharmTech (2652.HK) printed its session high of HK$5.755 at the 09:30 BJ open, slid to HK$5.375 by 11:39 and closed the afternoon at HK$5.430, down 5.65% on 1.075 million shares worth HK$5.89 million with a 0.33% turnover rate, extending October's retreat under small-cap liquidity pressure. The stock sits only 4.93% above its 52-week low of HK$5.175, 86.25% below the HK$39.50 peak of 25 February, down 84.01% year-to-date and well under MA20 of HK$6.817 and MA60 of HK$11.725. That contrasts with Q2 2026 revenue of HK$121.37 million, up 58.37% year on year, a net loss narrowing 60.58% to HK$6.07 million, and price-to-book of 1.52x, against Q1 revenue that fell 18.02% year on year. Though chairman Liang Wenqing added 19,300 shares near HK$6.92 each, management extended its lock-up by six months and repurchases of about HK$499,600 ran daily from 2 to 8 October, the shares still closed lower.
